Low-Dose Tofacitinib for Treating Patients with Severe Alopecia Areata: An Efficient and Cost-Saving Regimen

The study explored the use of low-dose tofacitinib as a treatment for severe alopecia areata (AA), highlighting its potential as an efficient and cost-saving regimen. Tofacitinib, a selective Janus kinase (JAK) 1 and 3 inhibitor, had been previously used at higher dosages of 10 to 20 mg daily for treating severe AA. However, the study aimed to evaluate the therapeutic response of a lower-dosage regimen, which had not been thoroughly assessed before. The lower dosage was suggested to offer clinical advantages, such as reduced medical costs and fewer potential adverse effects, making it a promising alternative for patients with severe AA.